Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.68 +1.4%	$4.06	$3.21 ▼ $8.06	$868.50M	0.59	4.52 million shs	4.96 million shs
CYRX CryoPort	$7.30 +11.3%	$6.26	$4.58 ▼ $9.78	$328.90M	1.85	526,298 shs	723,676 shs
GPCR Structure Therapeutics	$22.38 +1.3%	$23.39	$13.22 ▼ $47.48	$1.27B	-1.87	852,646 shs	1.06 million shs
IOVA Iovance Biotherapeutics	$1.88 +1.6%	$2.38	$1.64 ▼ $12.51	$617.78M	0.86	8.96 million shs	9.70 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+1.38%	+3.66%	-7.30%	-26.98%	-41.12%
CYRX CryoPort	+11.28%	+8.31%	+20.86%	+17.36%	-7.71%
GPCR Structure Therapeutics	+1.27%	+6.72%	-8.84%	+11.90%	-48.76%
IOVA Iovance Biotherapeutics	+1.62%	-6.93%	+5.62%	-45.35%	-76.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.1191 of 5 stars	3.5	1.0	4.4	2.7	2.5	0.6
CYRX CryoPort	3.6159 of 5 stars	4.4	3.0	0.0	1.8	3.3	0.6
GPCR Structure Therapeutics	2.289 of 5 stars	3.5	2.0	0.0	1.9	1.7	0.6
IOVA Iovance Biotherapeutics	4.6274 of 5 stars	4.3	1.0	4.2	1.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$10.89	195.89% Upside
CYRX CryoPort	2.71	Moderate Buy	$11.00	50.68% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	240.33% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	550.12% Upside

Current Analyst Ratings Breakdown

Latest CYRX, IOVA, ARDX, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	2.64	N/A	N/A	$0.73 per share	5.04
CYRX CryoPort	$228.38M	1.60	N/A	N/A	$7.44 per share	0.98
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
IOVA Iovance Biotherapeutics	$164.07M	3.83	N/A	N/A	$2.33 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	11.87	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
CYRX CryoPort	-$114.76M	-$2.34	N/A	N/A	N/A	-50.15%	-11.03%	-5.54%	8/5/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)

Latest CYRX, IOVA, ARDX, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/7/2025	Q1 2025	CYRX CryoPort	-$0.23	-$0.22	+$0.01	-$0.28	$56.19 million	$41.04 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.04	4.12	3.81
CYRX CryoPort	0.51	5.56	5.24
GPCR Structure Therapeutics	N/A	23.29	23.29
IOVA Iovance Biotherapeutics	N/A	4.18	3.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
CYRX CryoPort	92.90%
GPCR Structure Therapeutics	91.78%
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
CYRX CryoPort	10.10%
GPCR Structure Therapeutics	9.43%
IOVA Iovance Biotherapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
CYRX CryoPort	1,186	50.14 million	45.07 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable

CYRX, IOVA, ARDX, and GPCR Headlines

Recent News About These Companies

Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline

June 24 at 4:17 PM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

June 24 at 12:03 PM | globenewswire.com

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

June 24 at 9:00 AM | prnewswire.com

Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA

June 24 at 9:00 AM | prnewswire.com

IOVA STOCK LOSS: Iovance Biotherapeutics Shareholders are Alerted of Imminent July 14 Class Action Deadline -- Contact BFA Law (NASDAQ:IOVA)

June 24 at 8:18 AM | globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

June 23 at 4:05 PM | globenewswire.com

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

June 23 at 3:34 PM | globenewswire.com

ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

June 23 at 2:08 PM | globenewswire.com

Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

June 23 at 1:00 PM | globenewswire.com

Scott+Scott Attorneys at Law LLP Reminds Investors Of The Class Action That Has Been Filed Against Iovance Biotherapeutics, Inc. (IOVA)

June 23 at 12:16 PM | investing.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA

June 23 at 10:56 AM | globenewswire.com

Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - IOVA

June 23 at 9:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

June 22 at 10:00 AM | prnewswire.com

IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action -- Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)

June 22 at 9:33 AM | globenewswire.com

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA

June 21, 2025 | markets.businessinsider.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Assenagon Asset Management S.A.

June 21, 2025 | marketbeat.com

Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

June 20, 2025 | prnewswire.com

Gene Therapy Stocks Fall as FDA Pushes Out Another Top Regulator

June 20, 2025 | msn.com

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

June 20, 2025 | globenewswire.com

Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA

June 20, 2025 | prnewswire.com

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

June 20, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, IOVA, ARDX, and GPCR Company Descriptions

Ardelyx NASDAQ:ARDX

$3.68 +0.05 (+1.38%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$3.69 +0.01 (+0.38%)

As of 06/24/2025 07:37 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

CryoPort NASDAQ:CYRX

$7.30 +0.74 (+11.28%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$7.36 +0.06 (+0.75%)

As of 06/24/2025 07:44 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Structure Therapeutics NASDAQ:GPCR

$22.38 +0.28 (+1.27%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$22.49 +0.11 (+0.49%)

As of 06/24/2025 07:58 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Iovance Biotherapeutics NASDAQ:IOVA

$1.88 +0.03 (+1.62%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$1.89 +0.01 (+0.53%)

As of 06/24/2025 07:50 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time